PMID- 31712995
OWN - NLM
STAT- MEDLINE
DCOM- 20200513
LR  - 20200513
IS  - 1179-1969 (Electronic)
IS  - 1170-229X (Linking)
VI  - 37
IP  - 1
DP  - 2020 Jan
TI  - An Analysis of Real-World Data on the Safety of Etanercept in Older Patients with 
      Rheumatoid Arthritis.
PG  - 35-41
LID - 10.1007/s40266-019-00721-5 [doi]
AB  - OBJECTIVE: The aim of this study was to use real-world data to evaluate potential 
      interactions between age, treatment, and the risk of developing four adverse 
      events (AEs) common in the elderly: congestive heart failure, serious infections, 
      non-melanoma skin cancer, and interstitial lung disease. These AEs were 
      identified as important in a prior age-based analysis (</= 65 vs > 65 years) of 
      etanercept- or placebo-treated patients with rheumatoid arthritis (RA) in 
      controlled clinical trials. METHODS: Real-world data (1 January 2013 to 31 
      January 2018) were obtained from the IBM Watson Health MarketScan((R)) Database. 
      Patients were included if aged >/= 18 years, enrolled for >/= 1 year prior to RA 
      diagnosis, and without any of the four AEs of interest prior to RA diagnosis or 
      between RA diagnosis and first etanercept exposure. Logistic regression analysis 
      was applied following propensity matching of patients receiving or not receiving 
      etanercept based on age at diagnosis, age status at the beginning of observation 
      (> 65 years or not), sex, geographic region, and follow-up duration. RESULTS: The 
      overall cohort comprised 403,689 patients. The absolute risk of each of the four 
      AEs increased with age. In propensity-matched cohorts, etanercept was associated 
      with significantly higher odds of developing each of the four AEs (p < 0.001 for 
      all). However, the relative risk of experiencing the four AEs in patients who 
      received etanercept versus those who did not was similar between 
      patients </= 65 years of age and those > 65 years of age. CONCLUSIONS: In patients 
      with RA, the relative increase in etanercept-associated risk of experiencing 
      congestive heart failure, serious infection, non-melanoma skin cancer, or 
      interstitial lung disease was similar between elderly and non-elderly.
FAU - Edwards, Christopher J
AU  - Edwards CJ
AD  - Rheumatology Department, NIHR Clinical Research Facility, University Hospital 
      Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, UK. 
      cedwards@soton.ac.uk.
FAU - Bukowski, Jack F
AU  - Bukowski JF
AD  - Pfizer, Collegeville, PA, USA.
FAU - Burns, Sara M
AU  - Burns SM
AD  - Pfizer, Cambridge, MA, USA.
FAU - Jones, Heather E
AU  - Jones HE
AD  - Pfizer, Collegeville, PA, USA.
FAU - Pedersen, Ron
AU  - Pedersen R
AD  - Pfizer, Collegeville, PA, USA.
FAU - Sopczynski, Joan
AU  - Sopczynski J
AD  - Pfizer, Collegeville, PA, USA.
FAU - Marshall, Lisa
AU  - Marshall L
AD  - Pfizer, Collegeville, PA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Antirheumatic Agents)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Aged
MH  - Antirheumatic Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Cohort Studies
MH  - Databases, Factual
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology/etiology
MH  - Etanercept/administration & dosage/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2019/11/13 06:00
MHDA- 2020/05/14 06:00
CRDT- 2019/11/13 06:00
PHST- 2019/11/13 06:00 [pubmed]
PHST- 2020/05/14 06:00 [medline]
PHST- 2019/11/13 06:00 [entrez]
AID - 10.1007/s40266-019-00721-5 [pii]
AID - 10.1007/s40266-019-00721-5 [doi]
PST - ppublish
SO  - Drugs Aging. 2020 Jan;37(1):35-41. doi: 10.1007/s40266-019-00721-5.